Combined liver and kidney transplantation

Area of Science:

• Transplantation immunology
• Nephrology
• Hepatology
• Surgical outcomes

Background:

• End-stage renal and hepatic failure often require combined organ transplantation.
• Congenital hepatic anomalies are a significant indication for combined liver and kidney transplantation (CLKTx) in young patients.
• Previous outcomes for CLKTx were reviewed to establish benchmarks.

Purpose of the Study:

• To review the indications and outcomes of combined liver and kidney transplantation (CLKTx).
• To evaluate the efficacy of cyclosporin-based immunosuppression in CLKTx recipients.
• To assess long-term patient and graft survival rates following CLKTx.

Main Methods:

• Retrospective review of 16 combined liver and kidney transplants (CLKTx) performed between 1980 and 1994.
• Analysis of patient demographics, indications for transplantation, immunosuppression protocols, and follow-up data.
• Cyclosporin-based immunosuppression was utilized in the majority of cases.

Main Results:

• 87.5% of recipients were young patients with congenital hepatic anomalies and end-stage renal failure.
• With an average 6-year follow-up, patient survival was 85.7%, liver graft survival 85.7%, and kidney graft survival 72%.
• Rejection episode rates were comparable to solitary liver or kidney transplants.

Conclusions:

• Combined liver and kidney transplantation (CLKTx) is a valuable therapeutic option for patients with simultaneous end-stage renal and hepatic failure.
• CLKTx is particularly effective for young patients with congenital hepatic anomalies leading to renal failure.
• The study supports the use of CLKTx, demonstrating favorable long-term survival and manageable rejection rates.